Should a patient with a positive Clostridioides difficile glutamate dehydrogenase (GDH) antigen and a negative toxin A/B result be treated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

GDH-Positive, Toxin A/B-Negative Results: Further Testing Required Before Treatment Decision

A patient with positive C. difficile GDH antigen and negative toxin A/B should NOT be treated immediately but requires confirmatory testing with either NAAT (PCR) or toxigenic culture, as this discordant result represents an indeterminate state that could indicate either non-toxigenic colonization (~20% of C. difficile strains) or true toxigenic infection with toxin levels below the EIA detection threshold. 1

The Diagnostic Dilemma of GDH+/Toxin-Negative Results

The core issue is that GDH cannot differentiate between toxigenic and non-toxigenic C. difficile strains 1. When you encounter this discordant pattern:

  • Approximately 63% of GDH+/toxin-negative specimens harbor toxigenic C. difficile when subjected to culture and confirmatory testing 2
  • The remaining ~37% represent either non-toxigenic colonization or false-positive GDH results 2
  • This means treatment without confirmation would result in unnecessary antibiotics in over one-third of cases 1

The Three-Step Algorithm: What Guidelines Recommend

European guidelines explicitly state that GDH-positive but toxin-negative samples require testing with a reference method as a third step 1. The recommended approach:

Step 1: GDH Screening (Already Done - Positive)

  • High sensitivity (89-93%) but cannot confirm infection alone 1, 3
  • Negative predictive value of 100% in most studies 3

Step 2: Toxin A/B EIA (Already Done - Negative)

  • Your result shows no detectable toxin by EIA 1
  • However, toxin EIA has suboptimal sensitivity (32-98%), missing many true cases 1

Step 3: Confirmatory Testing (Required Now)

You must perform ONE of the following:

  • NAAT/PCR for toxin genes (tcdB): Sensitivity 80-100%, specificity 87-99% 1, 4
  • Toxigenic culture with cytotoxicity assay: Gold standard but slower (24-48 hours) 1

Clinical Context Matters for Interpretation

While awaiting confirmatory results, assess clinical probability:

High suspicion for true CDI (consider empiric treatment while testing): 1, 5

  • ≥3 unformed stools in 24 hours
  • Recent antibiotic exposure (within 8 weeks)
  • Hospitalization or healthcare facility exposure
  • Fever, leukocytosis, abdominal pain
  • Elevated creatinine or lactate

Lower suspicion (await results before treating): 5

  • Formed stool (should not have been tested)
  • No recent antibiotic exposure
  • Chronic diarrhea without acute change
  • Alternative diagnosis more likely

Performance Data Supporting This Approach

The two-step algorithm (GDH → toxin EIA) followed by confirmatory testing achieves:

  • Sensitivity: 94% 4
  • Specificity: 99% 4
  • Negative predictive value: 99% 4
  • Results available within 4 hours for 92% of specimens 6

In contrast, stopping at toxin EIA alone misses 61% of true CDI cases (sensitivity only 39%) 4.

Critical Pitfalls to Avoid

  • Never treat based on GDH alone - this leads to overtreatment of non-toxigenic colonization 1
  • Do not assume toxin-negative means no infection - toxin EIA has poor sensitivity 1, 4
  • Do not test asymptomatic patients or formed stool - this generates false positives requiring unnecessary workup 1, 5
  • Avoid repeat testing within 7 days unless clinical status changes significantly 7

If NAAT/PCR is Positive

  • Treat as CDI if clinically symptomatic with ≥3 unformed stools 1, 5
  • Recognize this confirms presence of toxigenic strain 7

If NAAT/PCR is Negative

  • Do not treat - this represents non-toxigenic colonization 1
  • Consider alternative diagnoses for diarrhea 8
  • Approximately 20% of C. difficile strains are non-toxigenic 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Confirming a Positive C. difficile Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

C. difficile Toxin Amplified Probe Tests

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Differential Diagnoses for Chronic Large Bowel Diarrhea with Positive C. difficile GDH and Toxin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the management approach for a patient with glutamate dehydrogenase (GDH) antigen positivity suggestive of Clostridioides difficile infection?
What are the differential diagnoses for a patient with chronic large bowel diarrhea and a confirmed Clostridioides difficile (C. difficile) infection, as indicated by exotoxin and glutamate dehydrogenase (GDH) positivity?
Do you treat a patient with Clostridioides difficile infection (CDI) who is polymerase chain reaction (PCR) positive, antigen positive but toxin negative?
What are the next steps for a patient with a positive Clostridioides difficile (C. diff) glutamate dehydrogenase (GDH) test and negative C. diff toxin A and B tests?
How to treat a patient with positive C. difficile antigen and toxins but negative PCR?
What additional diagnostic workup is indicated for a patient with bilateral eyelid edema without cardiac or pulmonary symptoms?
What is the most appropriate investigation before prescribing contraception to a 41‑year‑old woman with six months of abnormal uterine bleeding?
In a 68-year-old patient with persistent insomnia while taking zolpidem and escitalopram 10 mg daily, can a low-dose trial of mirtazapine be attempted?
What is the recommended unfractionated heparin regimen for routine intermittent hemodialysis in adult patients without high bleeding risk or heparin‑induced thrombocytopenia, and how should the dosing be adjusted for patients with increased bleeding risk or suspected/confirmed HIT?
In a 41-year-old woman with six months of abnormal uterine bleeding who requests contraception, what is the most appropriate investigation?
How should I evaluate and manage a patient with a persistent dry cough and scratchy throat five years after lung transplantation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.